<\/p>\n
Mirago<\/strong> bevat mirabegron 25 mg<\/strong> (extended-release tablet) — the first-in-class beta-3 (\u03b23) adrenergic receptor agonist<\/strong> voor de behandeling van overactieve blaas (OAB)<\/strong>. Unlike older anticholinergic OAB drugs (oxybutynin, tolterodine, solifenacin), mirabegron works by relaxing detrusor smooth muscle DURING bladder filling rather than blocking acetylcholine receptors. The result: similar efficacy without the dry mouth, constipation, blurred vision, cognitive slowing, and fall risk that limit anticholinergics in older patients. Standard dose: one 25 mg tablet once daily<\/strong>; can be increased to 50 mg\/day after 4-8 weeks if response is inadequate. Take with or without food. The 2023 American Geriatrics Society Beers Criteria flags all anticholinergic OAB drugs as “potentially inappropriate” in adults aged 65+<\/strong> — making mirabegron the preferred first-line OAB drug in this population. Meest voorkomende bijwerkingen:<\/strong> small increase in blood pressure (monitor BP at start), tachycardia, urinary tract infection, headache, nasopharyngitis. Contraindicated in severe uncontrolled hypertension<\/strong>.<\/p>\n<\/div>\n \ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n <\/p>\n Elke batch wordt ingekocht bij een WHO-GMP gecertificeerde fabrikant<\/strong>. Bestellingen worden verzonden in eenvoudige, ongemarkeerde verpakkingen door onze logistieke partners en vallen onder onze Reshipment Assurance Policy<\/a>: als een pakket niet binnen 20 werkdagen arriveert, sturen wij kosteloos een nieuwe zending, zonder vragen te stellen.<\/p>\n Mirago is a brand of mirabegron 25 mg extended-release tablet<\/strong>. Mirabegron is the first — and remains the dominant — \u03b23-adrenergic receptor agonist for the treatment of overactive bladder. Internationally branded as Myrbetriq (US), Betmiga (UK \/ EU), Mirabegron generic<\/strong>. Pack sizes available at MedsBase: 30, 60, 90 or 180 tablets.<\/p>\n The bladder detrusor muscle has both contractile<\/strong> (M3 muscarinic acetylcholine receptors) and relaxant<\/strong> (\u03b23 adrenergic receptors) inputs. During bladder filling, sympathetic nerve activity stimulates \u03b23 receptors, allowing the detrusor to relax and the bladder to accommodate increasing volumes without triggering urgency or contraction.<\/p>\n In overactive bladder, this filling-phase relaxation is impaired — the detrusor contracts inappropriately at low volumes, producing urgency, frequency, and urge incontinence. Mirabegron is a selective \u03b23 agonist<\/strong>: it amplifies the natural relaxation signal during filling, increasing functional bladder capacity and reducing the urgency-frequency-incontinence triad.<\/p>\n Crucially, mirabegron does NOT block muscarinic acetylcholine receptors — so it does not cause the dry mouth, constipation, blurred vision, urinary retention, cognitive slowing, or anticholinergic fall risk that have always limited oxybutynin, tolterodine, solifenacin, and the other antimuscarinic OAB drugs. This benefit is most relevant in older adults and in patients on multiple anticholinergic medications.<\/p>\n Mirabegron causes a small but measurable increase in blood pressure (typically 1-3 mmHg systolic at standard doses, slightly more at 50 mg). For most patients this is clinically irrelevant. For patients with pre-existing hypertension:<\/p>\n Do not take mirabegron if you have:<\/strong><\/p>\n Wees voorzichtig bij:<\/strong> bladder outlet obstruction (urinary retention risk, especially when combined with anticholinergic OAB drugs), congenital or acquired QT prolongation, controlled hypertension, history of angioedema.<\/p>\nWaarom bestellen bij MedsBase<\/h3>\n
\n
What is Mirago?<\/h2>\n
How mirabegron works<\/h2>\n
When mirabegron is used<\/h2>\n
\n
Dosering & hoe in te nemen<\/h2>\n
\n
Bijwerkingen & veiligheid<\/h2>\n
\n
Blood pressure monitoring<\/h2>\n
\n
Contra-indicaties & waarschuwingen<\/h2>\n
\n
Geneesmiddelinteracties<\/h2>\n
\n
Mirabegron vs anticholinergic OAB drugs<\/h2>\n